Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [820]

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Patterns of recurrence after a radical nephroureterectomy in high-risk upper...

Dr Alberto Martini - Vita-Salute San Raffaele University, Milan, Italy

Patterns of recurrence after a radical nephroureterectomy in high-risk upper tract urothelial carcinoma ( Dr Alberto Martini - Vita-Salute San Raffaele University, Milan, Italy )

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with...

Dr Jonathan Spicer - McGill University, Montreal, Canada

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Changes in cancer patient management in India during the pandemic

Prof Geetu Bhandoria - Command Hospital, Kolkata, India

Changes in cancer patient management in India during the pandemic ( Prof Geetu Bhandoria - Command Hospital, Kolkata, India )

ERAS in gynaecological oncology from developed to developing countries

Prof Geetu Bhandoria - Command Hospital, Kolkata, India

ERAS in gynaecological oncology from developed to developing countries ( Prof Geetu Bhandoria - Command Hospital, Kolkata, India )

More from ecancer